Genoptix (Genoptix) Shares Outstanding (Diluted Average) : 0.00 Mil (As of Sep. 2010)

View and export this data going back to . Start your Free Trial

What is Genoptix Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Genoptix's average diluted shares outstanding for the quarter that ended in Sep. 2010 was 0.00 Mil.

Genoptix Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Genoptix's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genoptix Shares Outstanding (Diluted Average) Chart

Genoptix Annual Data

Trend

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

Genoptix Quarterly Data
	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															-	-	-	-	-

Genoptix Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Genoptix (DELISTED:GXDX) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Genoptix Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Genoptix's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genoptix (Genoptix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genoptix Inc (DELISTED:GXDX) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Genoptix, Inc. incorporated in Delaware in January 1999. It is a specialized laboratory service provider, which is focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists, or hem/oncs. Its group of hematopathologists utilizes diagnostic technologies to provide a differentiated, specialized and integrated assessment of a patient's condition, aiding hem/oncs in making vital decisions concerning the treatment of malignancies of the blood and bone marrow, and other forms of cancer. The company's key service offerings, COMPASS and CHART, are designed to meet the specific needs of community-based hem/oncs. Its COMPASS service offering includes the determination by its hempaths of the appropriate diagnostic tests to be conducted and the performance of these tests. It then evaluate, synthesize and summarize the results into an easy to read comprehensive report, and its hempaths are available to interpret these results jointly with the hem/onc, giving them the benefit of its expertise and analytical experience. The company's CHART service offering combines multiple COMPASS assessments and analyses of disease progression after intervening clinical action, providing the hem/onc with a valuable diagnostic tool to track both a patient's disease and response to the hem/onc's prescribed treatment regimen over time. The Company believes its sales and marketing approach distinguishes it from its competitors. Most of its sales representatives have a four-year Bachelor of Science or Arts degree, primarily in the biological sciences, and a three-to five-year history selling diagnostic services or niche pharmaceuticals directly to hem/oncs. As a specialized diagnostic service provider, it relies extensively on its quality of service to attract and retain community-based hem/oncs and other healthcare professionals as its customers. As a diagnostic service provider, the Company is required to hold certain federal, state and local licenses, certifications and permits to conduct its business.

Genoptix (Genoptix) Headlines

No Headlines